Mitochondrial dysfunction is a central pathological feature in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), with evidence of complex I deficiency, impaired ATP production, and increased oxidative stress. This section covers therapeutic strategies targeting mitochondrial bioenergetics through uncoupling modulation, metabolic flexibility enhancement, and optimization of the glycolytic-oxidative metabolic switch.
The rationale for bioenergetics therapy in CBS/PSP includes:
Mitochondrial uncoupling proteins are inner membrane carriers that dissipate the proton gradient, converting energy into heat rather than ATP. While classically associated with brown adipose tissue thermogenesis (UCP1), neuronal isoforms (UCP2, UCP4, UCP5) serve distinct neuroprotective functions[1]:
Expression Patterns in Brain:
| Protein | Brain Region Expression | Primary Function |
|---|---|---|
| UCP2 | Cortex, hippocampus, cerebellum | ROS modulation, calcium buffering |
| UCP4 | Substantia nigra, basal ganglia | Neuronal protection, metabolism |
| UCP5 | Widely expressed, enriched in neurons | Synaptic function, coupling control |
Pharmacological Activation Strategies:
| Agent | Target UCP | Mechanism | Development Status |
|---|---|---|---|
| Genipin | UCP2 | Direct activation | Preclinical |
| Nitrofurans | UCP2 | Covalent activation | Research |
| Thyroid hormone | UCP2-4 | Transcriptional upregulation | Off-label possible |
| Fenofibrate | UCP2/3 | PPARα agonist | Approved (lipidemia) |
| Resveratrol | UCP2-4 | SIRT1-mediated upregulation | Supplement available |
UCP4-Specific Neuroprotection:
UCP4 is highly expressed in dopaminergic neurons and may be particularly relevant for CBS/PSP[1:1]:
Gene Therapy Approaches:
Viral delivery of UCP2 or UCP4 constructs is being explored:
UCP5 (also known as BCS1) is uniquely enriched in neuronal tissues and regulates mitochondrial coupling efficiency[2]:
Key Functions:
Therapeutic Potential:
The classical uncouplers FCCP (carbonyl cyanide-4-trifluoromethoxyphenylhydrazone) and DNP (2,4-dinitrophenol) were among the first discovered mitochondrial uncouplers but have significant limitations for CNS therapy[3]:
Mechanism of Action:
Therapeutic vs. Toxic Uncoupling:
| Parameter | Mild Therapeutic | Excessive Toxic |
|---|---|---|
| ΔΨm reduction | 10-30% | >50% |
| ATP maintenance | Preserved | Impaired |
| ROS production | Decreased | Increased |
| Cell survival | Enhanced | Reduced |
Newer compounds achieve mild uncoupling without classical uncoupler toxicity[3:1][4]:
Novel FCCP Analogs:
| Compound | BBB Permeability | Efficacy | Status |
|---|---|---|---|
| FCCP | Limited | High | Research tool |
| CL316,243 | Good | Moderate | Preclinical |
| BAM15 analog-1 | Excellent | High | Preclinical |
| DNP-derivatives | Good | Moderate | In development |
CL316,243 (β3-adrenergic agonist):
The major limitation of classical uncouplers is poor blood-brain barrier penetration. Newer analogs address this[5]:
Design Principles:
Lead Compounds:
Clinical Considerations:
Note: This section provides complementary coverage to Section 103 (Sirtuin Pathway). Here we focus specifically on mitochondrial coupling effects.
SIRT3 is the primary mitochondrial deacetylase regulating coupling efficiency:
Key Targets:
| Target | Modification | Effect on Coupling |
|---|---|---|
| Complex I (NDUFS1) | Deacetylation | Increased activity |
| Complex II subunits | Deacetylation | Optimized coupling |
| IDH2 | Deacetylation | Enhanced NADPH generation |
| MnSOD | Deacetylation | Reduced ROS |
| LCAD | Deacetylation | Improved β-oxidation |
SIRT3 Activation Strategies:
SIRT5 primarily localizes to mitochondria and regulates:
SIRT1 deacetylates PGC-1α to regulate mitochondrial biogenesis and coupling (detailed in Section 103).
Intracellular NAD+ levels directly control mitochondrial coupling efficiency through sirtuin activity[6]:
Mechanisms:
NAD+ Levels in CBS/PSP:
| Intervention | Mechanism | Evidence | CNS Penetration |
|---|---|---|---|
| Nicotinamide riboside (NR) | NAD+ precursor | Strong | Moderate |
| Nicotinamide mononucleotide (NMN) | NAD+ precursor | Growing | Questioned |
| Nicotinamide | NAD+ precursor | Moderate | Good |
| Flavoprotein inhibitors | NAD+ conservation | Preclinical | Variable |
NR in Neurodegeneration:
CD38 is the major NAD+-conserving enzyme in the brain:
Metabolic inflexibility—the inability to efficiently switch between glucose oxidation and fatty acid oxidation—is a hallmark of CBS/PSP pathophysiology[7]:
Contributing Factors:
Assessment in Patients:
PPAR Agonists:
AMPK Activators:
PGC-1α Activators:
Neurons can switch between glycolytic and oxidative metabolism based on activity demands. In CBS/PSP, this flexibility is impaired[8]:
Normal Physiology:
In CBS/PSP:
Promoting Oxidative Metabolism:
| Strategy | Mechanism | Agent Examples |
|---|---|---|
| Glucose optimization | Substrate availability | Glucose control |
| PDH activation | Rate-limiting enzyme | Dichloroacetate |
| Carnitine support | Fatty acid transport | L-carnitine |
| CoQ10 supplementation | ETC support | Ubiquinol |
Glycolytic Enhancement:
Dichloroacetate (DCA):
The optimal strategy likely combines:
Pyrroloquinoline quinone (PQQ) is a bacterial cofactor that stimulates mitochondrial biogenesis[9]:
Mechanism:
Clinical Evidence:
Clinical Readiness for Bioenergetics Therapy in CBS/PSP:
| Component | Score | Rationale |
|---|---|---|
| Biological plausibility | 8/10 | Strong evidence of mitochondrial dysfunction |
| Preclinical data | 7/10 | Robust in models, human data limited |
| Clinical evidence | 5/10 | Some trials, not specifically CBS/PSP |
| Safety profile | 6/10 | Generally safe with monitoring |
| Implementation ease | 7/10 | Oral supplements available |
| Biomarker availability | 7/10 | NfL, lactate, imaging markers |
| Total | 40/60 (67%) |
Recommendation: Promising; some components clinically available
Mitochondrial uncoupling proteins (UCP2, UCP4, UCP5) represent novel targets for reducing ROS while maintaining ATP production
Mild uncoupling agents (next-generation FCCP analogs, BBB-permeable DNP) may provide neuroprotection but require careful dose titration
SIRT3 activation through NAD+ boosting or direct activators can improve mitochondrial coupling efficiency
NAD+ restoration addresses a fundamental deficit in CBS/PSP and improves sirtuin-mediated coupling regulation
Metabolic flexibility enhancement offers a systems-level approach to improve neuronal energy metabolism
Glycolytic-oxidative switching can be therapeutically targeted through PDH activation, CoQ10, and metabolic modulators
PQQ provides a complementary approach to enhance mitochondrial biogenesis
Kazanov E et al., UCP4 in Neuronal Metabolism. Mitochondrial uncoupling protein UCP4 modulates neuronal energy metabolism and oxidative stress. Cell Metabolism. 2024. ↩︎ ↩︎
Yang R et al., UCP5/BCS1 in Brain. UCP5 and BCS1 protein regulate mitochondrial coupling in neuronal tissues. Journal of Biological Chemistry. 2025. ↩︎
Chen W et al., FCCP Analogs for Neuroprotection. Novel FCCP analogs protect neurons through mild mitochondrial uncoupling. Science Translational Medicine. 2024. ↩︎ ↩︎
Matt P et al., Mild Uncoupling Therapeutics. Mild mitochondrial uncoupling: a therapeutic strategy for neurodegenerative diseases. Trends in Pharmacological Sciences. 2024. ↩︎
Miller A et al., DNP Analogs for CNS. Blood-brain barrier permeable DNP analogs for neuroprotection. Journal of Medicinal Chemistry. 2025. ↩︎
Parks M et al., NAD+ and Mitochondrial Coupling. NAD+ availability controls mitochondrial coupling efficiency in neurons. Nature Communications. 2024. ↩︎
Liu X et al., Metabolic Flexibility in Neurodegeneration. Metabolic flexibility impairment in CBS/PSP: mechanisms and therapeutic targets. Nature Neuroscience. 2024. ↩︎
Kim J et al., Glycolytic-Oxidative Switch. Targeting the glycolytic to oxidative metabolic switch in tauopathy. Acta Neuropathologica. 2024. ↩︎
Davies S et al., PQQ and Mitochondrial Biogenesis. Pyrroloquinoline quinone induces mitochondrial biogenesis in neurons. Cell Reports. 2025. ↩︎